Novartis AG and Gilead Sciences Inc.'s recently acquired subsidiary Kite Pharma Inc. have the only two approved chimeric antigen receptor T cell (CAR-T) therapies, but bluebird bio Inc. and its partner Celgene Corp. were the stars of the recent American Society of Hematology (ASH) annual meeting.
Both Novartis' Kymriah (tisagenlecleucel) and Gilead/Kite's Yescarta (axicabtagene ciloleucel) are comprised of patients' own T cells reengineered to target cancer...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?